Big Pharma CEOs decide to show up at Senate pricing hearings by Eric Sagonowsky Wednesday, February 6, 2019 Sen. Charles Grassley, R-Iowa, vowed to haul pharma CEOs into Senate drug-pricing hearings. Now, several have heeded the call.
Merck analysts to CEO Frazier: What’s so great about the pipeline? by Arlene Weintraub Friday, February 1, 2019 Merck's 2019 sales expectations are on the low side of what analysts expected, intensifying concerns about growth beyond I-O star Keytruda.
Merck's long M&A dry spell isn't for lack of trying: CEO by Carly Helfand Tuesday, January 8, 2019 There’s a reason Merck hasn’t made a big acquisition lately. And it’s not because it doesn’t want to.
Merck, Pfizer CEOs strike discordant tones on drug prices by Eric Sagonowsky Friday, November 2, 2018 There's been no shortage of drug pricing talk in recent weeks, and now Merck's and Pfizer's CEOs have had a chance to voice their thoughts.
Merck CEO scouts growth beyond high-flying Keytruda by Arlene Weintraub Thursday, October 25, 2018 Merck & Co. has a jet engine for growth in its oncology star Keytruda, but long-term it needs more than cancer to keep growth coming.
Bayer draws on past tactics in fighting Roundup cases by Eric Sagonowsky Wednesday, October 24, 2018 A judge struck a large portion of a Roundup verdict against Bayer, but as thousands of lawsuits pile up, the litigation is just getting started.
Pharma CEOs lean GOP this election—all but one, that is by Eric Sagonowsky Monday, October 22, 2018 Big biopharma CEOs gave most or all their campaign contributions to Republicans this season, but one went full blue with his $120,000.
Want a glimpse into pharma’s future? Look to cable: Merck CEO by Carly Helfand Thursday, October 4, 2018 There are a lot of intermediate players in today’s pharma supply chain. But expect that to change, Merck CEO Ken Frazier said Wednesday.
Frazier to remain Merck CEO as board drops mandatory retirement by Eric Palmer Wednesday, September 26, 2018 A policy change by the board of Merck & Co. will allow Ken Frazier to remain CEO after he turns 65 next year.
Merck's price cuts aren’t as benevolent as they seem: analysts by Arlene Weintraub Friday, July 20, 2018 A closer look at the Merck's new pricing plan reveals it really isn’t changing all that much, analysts say.